Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome

Cited by (281)

Items 101–200 of 281

1. Tau in Alzheimer’s Disease: Pathological Alterations and an Attractive Therapeutic Target
   Jianlan Gu, Fei Liu · 2020 · Current Medical Science
2. Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules
   Chiara Lanzillotta, Fabio Di Domenico · 2021 · Biomolecules
3. Developmental deficits and staging of dynamics of age associated Alzheimer’s disease neurodegeneration and neuronal loss in subjects with Down syndrome
   Jerzy Węgiel, Michael J. Flory, Izabela Kuchna, Krzysztof Nowicki, Jarek Wegiel, Shuang Yong Ma, Nanbert Zhong, Teresa Wierzba‐Bobrowicz, Mony de Leon, Florence Lai et al. · 2022 · Acta Neuropathologica Communications
4. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer’s Disease Mice by Targeting DYRK1A
   Yanni Liu, Lin Wang, Fuheng Xie, Xiao Wang, Yuanyuan Hou, Xiaomeng Wang, Juan Liu · 2020 · Current Neurovascular Research
5. Overexpression of Dyrk1A Causes the Defects in Synaptic Vesicle Endocytosis
   Yoonju Kim, Joo‐Hyun Park, Woo‐Joo Song, Sunghoe Chang · 2010 · Neurosignals
6. Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3β
   Giulia Povellato, Richard I. Tuxworth, Diane P. Hanger, Guy Tear · 2013 · Biology Open
7. Down syndrome is an oxidative phosphorylation disorder
   M. Pilar Bayona‐Bafaluy, Nuria Garrido-Pérez, Patricia Meade, Eldris Iglesias, Irene Jiménez-Salvador, Julio Montoya, Carmen Martínez‐Cué, Eduardo Ruiz‐Pesini · 2021 · Redox Biology
8. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects
   Yasmeen T. AlNajjar, Moustafa Tarek Gabr, Ahmed K. ElHady, Mohamed Salah, Gerrit Wilms, Alireza Abadi, Walter B. Becker, Mohammad Abdel‐Halim, Matthias Engel · 2021 · European Journal of Medicinal Chemistry
9. The in vivo Down syndrome genomic library in mouse
   Yann Hérault, Arnaud Duchon, Émilie Velot, Damien Maréchal, Véronique Brault · 2012 · Progress in brain research
10. APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer’s pathology in trisomy 21 neurons
    Chun-I Wu, Elizabeth A. Vinton, Richard V. Pearse, Keunjung Heo, Aimee J. Aylward, Yi‐Chen Hsieh, Yan Bi, Sopefoluwa Adeleye, Seeley B. Fancher, Duc Minh Duong et al. · 2022 · Molecular Psychiatry
11. First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer’s Disease
    Marica Mariano, Christian Schmitt, Parisa Miralinaghi, Marco Catto, Rolf W. Hartmann, Angelo Carotti, Matthias Engel · 2014 · ACS Chemical Neuroscience
12. Structure–Activity Relationship in the Leucettine Family of Kinase Inhibitors
    Tania Tahtouh, Émilie Durieu, Benoît Villiers, Céline Bruyère, Thu Lan Nguyen, Xavier Fant, Kwang H. Ahn, Leepakshi Khurana, Emmanuel Deau, Mattias F. Lindberg et al. · 2021 · Journal of Medicinal Chemistry
13. Candidate gene analysis for Alzheimer's disease in adults with Down syndrome
    Joseph Hyungwoo Lee, Annie Lee, Lam‐Ha T. Dang, Deborah I. Pang, Sergey Kisselev, Sharon J. Krinsky‐McHale, Warren B. Zigman, Jose Alejandro Luchsinger, Wayne P. Silverman, Benjamin Tycko et al. · 2017 · Neurobiology of Aging
14. DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease
    Márcia María de Souza, Arthur Ribeiro Cenci, Kerolain Faoro Teixeira, Valkiria Machado, Majory C.G.M. Schülerb, Ana Elisa Gonçalves, Ana Paula Dalmagro, Camila André Cazarin, Leonardo L. G. Ferreira, Aldo Sena de Oliveira et al. · 2022 · Current Medicinal Chemistry
15. Epidemiology of estrogen and dementia in women with Down syndrome
    Nicole Schupf, Joseph Hyungwoo Lee, Deborah I. Pang, Warren B. Zigman, Benjamin Tycko, Sharon J. Krinsky‐McHale, Wayne P. Silverman · 2017 · Free Radical Biology and Medicine
16. The physiological phosphorylation of tau is critically changed in fetal brains of individuals with Down syndrome
    Ivan Milenković, Jasna Jarc, Eva Dassler, Eleonora Aronica, Anand M. Iyer, Homa Adle‐Biassette, Anke Scharrer, Theresa Reischer, Johannes Andreas Hainfellner, Gábor Géza Kovács · 2017 · Neuropathology and Applied Neurobiology
17. Interactions between GSK3β and amyloid genes explain variance in amyloid burden
    Timothy J. Hohman, Mary Ellen I. Koran, Tricia A. Thornton‐Wells · 2013 · Neurobiology of Aging
18. Intracellular distribution of differentially phosphorylated dual‐specificity tyrosine phosphorylation‐regulated kinase 1A (DYRK1A)
    Wojciech Kaczmarski, Madhabi Barua, Bozena Mazur‐Kolecka, Janusz Frackowiak, Wieslaw K. Dowjat, Pankaj D Mehta, David Bolton, Yu‐Wen Hwang, Ausma Rabe, Giorgio Albertini et al. · 2013 · Journal of Neuroscience Research
19. Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome
    Carmen Martínez‐Cué, Noemı́ Rueda · 2020 · International Journal of Molecular Sciences
20. Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry
    Michael J. Ellis, Christiana Lekka, Katie L. Holden, Hanna Tulmin, Faheem Seedat, Darragh Patrick O'Brien, Shalinee Dhayal, Marie‐Louise Zeissler, Jakob Grunnet Knudsen, Benedikt Mathias Kessler et al. · 2024 · Acta Neuropathologica
21. GSKIP-Mediated Anchoring Increases Phosphorylation of Tau by PKA but Not by GSK3beta via cAMP/PKA/GSKIP/GSK3/Tau Axis Signaling in Cerebrospinal Fluid and iPS Cells in Alzheimer Disease
    Huey-Jiun Ko, Shean-Jaw Chiou, Yu‐Hui Wong, Yin-Hsuan Wang, Yun-Ling Lai, Chia‐Hua Chou, Chihuei Wang, Joon‐Khim Loh, Ann‐Shung Lieu, Jiin‐Tsuey Cheng et al. · 2019 · Journal of Clinical Medicine
22. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders
    Stefania Demuro, Conall Sauvey, Shailesh Kumar Tripathi, Rita Maria Concetta Di Martino, Da Shi, Jose Antonio Ortega, Debora Russo, Beatrice Balboni, Barbara Giabbai, Paola Storici et al. · 2021 · European Journal of Medicinal Chemistry
23. Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?
    Mirjam Brackhan, Marina Arribas-Blázquez, Isabel Lastres‐Becker · 2023 · Antioxidants
24. Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification
    Sarah S. Darwish, Mohammad Abdel‐Halim, Ahmed K. ElHady, Mohamed Salah, Alireza Abadi, Walter B. Becker, Matthias Engel · 2018 · European Journal of Medicinal Chemistry
25. Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay
    Di Wang, Fei Wang, Yexiong Tan, Liwei Dong, Lei Chen, Weiliang Zhu, Hongyang Wang · 2011 · Bioorganic & Medicinal Chemistry Letters
26. Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish
    Hyun-Ju Cho, Jae-Geun Lee, Seon‐Young Kim, Seon‐Young Kim, Yang Hoon Huh, Hyo‐Jeong Kim, Kyu‐Sun Lee, Kweon Yu, Jeong-Soo Lee · 2019 · Disease Models & Mechanisms
27. A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase
    Linh Chi Bui, Laure Tabouy, Florent Busi, Jean‐Marie Dupret, Nathalie Janel, Chris Planque, Jean Maurice Delabar, Fernando Rodrigues‐Lima, Julien Dairou · 2013 · Analytical Biochemistry
28. Basal forebrain cholinergic neurons are vulnerable in a mouse model of Down syndrome and their molecular fingerprint is rescued by maternal choline supplementation
    Melissa J. Alldred, Harshitha Pidikiti, Adriana Heguy, Panos Roussos, Stephen D. Ginsberg · 2023 · The FASEB Journal
29. Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice
    Glòria Arqué, María Martínez de Lagrán, Maria Lourdes Arbonés, Mara Dierssen · 2009 · Neurobiology of Disease
30. Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer’s disease: An integrative molecular modeling approach
    Rohit Shukla, Anuj Kumar, David J. Kelvin, Tiratha Raj Singh · 2023 · Frontiers in Molecular Biosciences
31. Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A
    Varsha Ananthapadmanabhan, Kathryn H. Shows, AMANDA J.G. DICKINSON, Larisa Litovchick · 2023 · Frontiers in Cell and Developmental Biology
32. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome
    Michael S. Rafii · 2018 · Developmental Neurobiology
33. Heterogeneous nuclear ribonucleoprotein E3 modestly activates splicing of tau exon 10 via its proximal downstream intron, a hotspot for frontotemporal dementia mutations
    Yan Wang, Lei Gao, Sze‐Wah Tse, Athena Andreadis · 2009 · Gene
34. Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome
    Wenche Stensen, Ulli Rothweiler, Richard Alan Engh, Melissa R. Stasko, Ilya R. Bederman, Alberto C. S. Costa, Anders Fugelli, John S. M. Svendsen · 2021 · Pharmaceuticals
35. Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches
    Farrell, Clíona, Mumford, Paige, Wiseman, Frances K. · 2022 · Frontiers in Neuroscience
36. Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors
    Areum Park, Jieon Hwang, Joo‐Youn Lee, Eun Ji Heo, Yoon-Ju Na, Sein Kang, Kyu-Sung Jeong, Ki Young Kim, Sang Joon Shin, Hyuk Lee · 2021 · Bioorganic & Medicinal Chemistry Letters
37. Discovery of novel harmine derivatives as GSK‐3β/DYRK1A dual inhibitors for Alzheimer's disease treatment
    Jingsong Qiu, Xiangling Feng, Huanhua Chen, Wenwu Liu, Wenjie Liu, Limeng Wu, Xudong Gao, Yanfang Liu, Yaoguang Huang, Hao Gong et al. · 2023 · Archiv der Pharmazie
38. Innovative pathological network‐based multitarget approaches for Alzheimer's disease treatment
    Paloma Mayo, Jorge Pascual-Guerra, Enrique Crisman, Cristina Domínguez, Manuela G. López, Rafael M. Leon · 2024 · Medicinal Research Reviews
39. Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
    Przemysław Radosław Kac, Daniel Andres Alcolea, Laia Montoliu‐Gaya, Susana Fernández, Juan Lantero‐Rodriguez, Lucía Maure‐Blesa, Fernando González‐Ortiz, Bessy Benejam, Michael Turton, Isabel Barroeta et al. · 2025 · Alzheimer s & Dementia
40. microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing
    Juliana C.S. Chaves, Felippe T. Machado, Michael Fernandes de Almeida, Tatiana B. Bacovsky, M Ferrari · 2019 · Neuroscience Letters
41. A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay
    Kyu‐Sun Lee, Miri Choi, Dae-Woo Kwon, Doyoun Kim, Jong-Moon Choi, Ae‐Kyeong Kim, Youngwook Ham, Sang‐Bae Han, Sungchan Cho, Chong Kun Cheon · 2020 · Scientific Reports
42. E3 Ligase SCFβTrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells*
    Qiang Liu, Yu Tang, Long Chen, Na Liu, Fangfang Lang, Heng Liu, Pin Wang, Xiu-Lian Sun · 2016 · Journal of Biological Chemistry
43. The Role of Tau Pathology in Alzheimer’s Disease and Down Syndrome
    Ann‐Charlotte Granholm, Eric Daniel Hamlett · 2024 · Journal of Clinical Medicine
44. The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
    E Torac, Laura Elena Gaman, Valeriu Atanasiu · 2014 · Europe PMC (PubMed Central)
45. Recent Understanding of the Molecular Mechanisms of Alzheimer?s Disease
    Marcus O.W. Grimm, Tobias Hartmann · 2011 · Journal of Addiction Research & Therapy
46. Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
    Caraci, Filippo, Iulita, M. Florencia, Pentz, Rowan, Flores Aguilar, Lisi, Orciani, Chiara, Barone, Concetta, Romano, Corrado, Drago, Filippo, Cuello, A. Claudio · 2017 · European Journal of Pharmacology
47. Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D
    Pin Wang, Luanluan Wang, Long Chen, Xiulian Sun · 2017 · Scientific Reports
48. Identification and analysis of a selective DYRK1A inhibitor
    Tony Eight Lin, Min‐Wu Chao, Wei‐Chun HuangFu, Huang‐Ju Tu, Zhaoxiang Peng, C SU, Tzu-Ying Sung, Jui‐Hua Hsieh, Chien‐Chung Lee, Chia‐Ron Yang et al. · 2021 · Biomedicine & Pharmacotherapy
49. Shaping down syndrome brain cognitive and molecular changes due to aging using adult animals from the Ts66Yah murine model
    Chiara Lanzillotta, Monika Rataj-Baniowska, Francesca Prestia, Chiara Sette, Valérie Nalesso, Marzia Perluigi A, Eugenio Barone, Arnaud Duchon, Antonella Tramutola, Yann Hérault et al. · 2024 · Neurobiology of Disease
50. Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core
    Mohamed Salah, Mohammad Abdel‐Halim, Matthias Engel · 2018 · MedChemComm
51. DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes
    Bangfu Zhu, Tom Parsons, Wenche Stensen, John S. M. Svendsen, Anders Fugelli, James J. L. Hodge · 2022 · Frontiers in Pharmacology
52. Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome
    Verónica Vidal, Susana García-Cerro, Paula M. Martinez, Andrea Corrales, Sara Lantigua, Rebeca Vidal, Noemı́ Rueda, Laurence Ozmen, Maria‐Clemencia Hernandez, Carmen Martínez‐Cué · 2017 · Molecular Neurobiology
53. Recent research and development of DYRK1A inhibitors
    Liyun Zhao, Xuan Xiong, Li Liu, Qi Liang, Rongsheng Tong, Xuanlin Feng, Lan Bai, Jianyou Shi · 2021 · Chinese Chemical Letters
54. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD)
    Pinky Gehlot, Rekha Pathak, Sunil Kumar, Naveen Kumar Choudhary, Vivek K. Vyas · 2024 · Bioorganic & Medicinal Chemistry
55. Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21
    Aarti Ruparelia, Frances K. Wiseman, Olivia Sheppard, Victor L. J. Tybulewicz, Elizabeth Fisher · 2010 · Journal of Biomedical Research
56. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule
    Wu, Yi-Wen, HuangFu, Wei-Chun, Lin, Tony Eight, Peng, Chao-Hsiang, Tu, Huang-Ju, Sung, Ting-Yi, Sung, Tzu-Ying, Yen, Shih-Chung, Pan, Shiow-Lin, Hsu, Kai-Cheng · 2024 · International Journal of Biological Macromolecules
57. Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis
    Gian Luca Araldi, Yu‐Wen Hwang · 2022 · Bioorganic & Medicinal Chemistry Letters
58. Dyrk1A-mediated phosphorylation of RCAN1 promotes the formation of insoluble RCAN1 aggregates
    Woo‐Joo Song, Eun‐Ah Christine Song, Sunhee Choi, Hyung-Hwan Baik, Byung Kwan Jin, Jeong Hee Kim, Sul‐Hee Chung · 2013 · Neuroscience Letters
59. C‐terminal truncation of GSK ‐3β enhances its dephosphorylation by PP 2A
    Nana Jin, Yue Wu, Wen Xu, Cheng‐Xin Gong, Khalid Iqbal, Fei Liu · 2017 · FEBS Letters
60. DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort
    José Luis Vázquez‐Higuera, Pascual Sánchez‐Juan, Eloy Rodríguez‐Rodríguez, Ignacio Mateo, Ana Pozueta, Ana Frank, Isabel Sastre, Fernando Valdivieso, José Berciano, Maria Jesus Bullido et al. · 2009 · BMC Medical Genetics
61. Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7
    Dandan Chu, Leyi Lei, Shu Ping Gu, Fei Liu, Feng Wu · 2024 · Biochemical Pharmacology
62. Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome
    Amal Kasri, Elena Camporesi, Eleni Gkanatsiou, Susana Boluda, Gunnar Brinkmalm, Lev Stimmer, Junyue Ge, Jörg Hanrieder, Nicolas Villain, Charles J. Duyckaerts et al. · 2024 · Acta Neuropathologica
63. Neuronal overexpression of Alzheimer's disease and Down's syndrome associated DYRK1A/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in Drosophila
    Simon A. Lowe, Maria M. Usowicz, James J. L. Hodge · 2019 · Neurobiology of Disease
64. Opportunities and Limitations of Modelling Alzheimer’s Disease with Induced Pluripotent Stem Cells
    Dmitry A. Ovchinnikov, Ernst Jurgen Wolvetang · 2014 · Journal of Clinical Medicine
65. Hypocellularity in the Murine Model for Down Syndrome Ts65Dn Is Not Affected by Adult Neurogenesis
    Rosa López‐Hidalgo, Raúl Ballestín, Jessica Vega, José Miguel Blasco‐Ibáñez, Carlos Crespo, Javier Gilabert‐Juan, Juan Nácher, Emilio Varea · 2016 · Frontiers in Neuroscience
66. Development of Novel Fluorinated Polyphenols as Selective Inhibitors of DYRK1A/B Kinase for Treatment of Neuroinflammatory Diseases including Parkinson’s Disease
    Gian Luca Araldi, Yu‐Wen Hwang · 2023 · Pharmaceuticals
67. Truncated Dyrk1A aggravates neuronal apoptosis by inhibiting ASF ‐mediated Bcl‐x exon 2b inclusion
    Shuqiang Zhang, Junjie Zhong, Xu Lian, Yue Wu, Jie Xu, Shi Jianhua, Zhikai Gu, Xiaoyu Li, Nana Jin · 2023 · CNS Neuroscience & Therapeutics
68. Importance of gene dosage in controlling dendritic arbor formation during development
    Tijana Copf · 2015 · European Journal of Neuroscience
69. Dyrk1a
    Walter B. Becker · 2008 · AfCS-Nature Molecule Pages
70. Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation
    Huang‐Ju Tu, Min‐Wu Chao, Chien‐Chung Lee, Chao-Shiang Peng, Yiwen Wu, Tony Eight Lin, Yu-Wei Chang, Shih‐Chung Yen, Kai‐Cheng Hsu, Shiow‐Lin Pan et al. · 2024 · Journal of Enzyme Inhibition and Medicinal Chemistry
71. DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
    Manon Moreau, María Carmona‐Iragui, Miren Altuna, Lorraine Dalzon, Isabel Barroeta, Marie Vilaire-Meunier, Sophie Durand, Juan Fortea, Anne‐Sophie Rebillat, Nathalie Janel · 2022 · Biomedicines
72. Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model
    Hawley, Laura E., Stringer, Megan, Deal, Abigail J., Folz, Andrew, Goodlett, Charles R., Roper, Randall J. · 2024 · Neurobiology of Disease
73. A novel inhibitor rescues cerebellar defects in a zebrafish model of Down syndrome–associated kinase Dyrk1A overexpression
    Astrid Buchberger, Lena Schepergerdes, Maren Flaßhoff, Conrad Kunick, Reinhard Wolfgang Köster · 2021 · Journal of Biological Chemistry
74. Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases
    Youssef Aboushady, Moustafa Tarek Gabr, Ahmed K. ElHady, Mohamed Salah, Alireza Abadi, Gerrit Wilms, Walter B. Becker, Mohammad Abdel‐Halim, Matthias Engel · 2021 · ACS Chemical Neuroscience
75. Evolving significance of kinase inhibitors in the management of Alzheimer's disease
    Md Mustafiz Ansari, Sanjeev Kumar Sahu, Thakur Gurjeet Singh, Sovia R.J. Singh, Paranjeet Kaur · 2024 · European Journal of Pharmacology
76. Unlocking the therapeutic potential of protein kinase inhibitors in neurodegenerative and psychiatric disorders
    Angela Asir R V, Polina Buzaeva, Izhak Michaelevski · 2025 · Exploration of Drug Science
77. Endogenous and Exogenous Factors in Hyperphosphorylation of Tau in Alzheimer′s Disease*
    Yan Wei, Jun-Ye MIAO, Ying Min Liu · 2012 · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
78. Tau seeding activity in various regions of down syndrome brain assessed by two novel assays
    Nana Jin, Jianlan Gu, Ruozhen Wu, Dandan Chu, Yunn Chyn Tung, Jerzy Węgiel, Thomas Wısnıewskı, Cheng‐Xin Gong, Khalid Iqbal, Fei Liu · 2022 · Acta Neuropathologica Communications
79. Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor
    Cayz G. Paclibar, Deanna M. Schafer, Agnes P. Biju, Fariha Karim, Stephanie A. Sison, Christopher Liang, Shamiha T. Ahmed, Jogeshwar Mukherjee · 2025 · Molecules
80. DYRK1A in the physiology and pathology of the neuron-astrocyte axis
    Pablo Cisternas, Ji-Yoon Kim, Brandon L. Ashfeld, Jeremiah J. Zartman · 2025 · Frontiers in Neuroscience
81. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation
    Nianzhuang Qiu, Chenliang Qian, Tingting Guo, Yaling Wang, Hongwei Jin, Mingli Yao, Mei Li, Tianyang Guo, Yuli Lv, Xinxin Si et al. · 2024 · International Journal of Biological Macromolecules
82. Rational Design and Identification of Harmine‐Inspired, N ‐Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System**
    Francisco J. Huizar, Harrison M. Hill, Emily P. Bacher, Kaitlyn E. Eckert, Eva M. Gulotty, Kevin X. Rodriguez, Zachary D. Tucker, Monimoy Banerjee, Haining Liu, Olaf Wiest et al. · 2022 · ChemMedChem
83. Unlocking the Therapeutic Potential of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitors in Alzheimer’s Diseases
    Dipanjan Karati, Shreyasi Meur, Ankur Saha, Trina Saha, Aratrika Sen · 2025 · Molecular Neurobiology
84. Epigenetics and Down syndrome
    Luis Alfonso González-Molina, Alain D. Dekker, Peter Paul De Deyn, Amalia M. Dolga, Marianne G. Rots · 2024 · Elsevier eBooks
85. Mitochondrial Imbalance in Down Syndrome: A Driver of Accelerated Brain Aging?
    Xinxin Zuo · 2025 · Aging and Disease
86. A high‐content drug screening strategy to identify protein level modulators for genetic diseases: A proof‐of‐principle in autosomal dominant leukodystrophy
    Elisa Giorgio, Emanuela Pesce, Elisa Pozzi, Elvira Sondo, Marta Ferrero, Cristina Morerio, Giusy Borrelli, Edoardo Della Sala, Martina Lorenzati, Pietro Cortelli et al. · 2020 · Human Mutation
87. Kinase inhibition in Alzheimer’s disease
    Soghra Bagheri, Ali Akbar Saboury · 2022 · Elsevier eBooks
88. A patient with Down syndrome with a de novo derivative chromosome 21
    Zafer Çetin, Sezin Yakut, Ercan Mıhçı, Ayşe Esra Manguoğlu, Sibel Berker, İbrahim Keser, Güven Lüleci · 2012 · Gene
89. In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome
    Gaëlle Naert, Valentine Marie Ferré, Emeline Keller, Amy Slender, Dorota Gibbins, Elizabeth Fisher, Victor L. J. Tybulewicz, Tangui Maurice · 2017 · Journal of Psychopharmacology
90. A large kinome in a large cell: Stentor coeruleus possesses highly expanded kinase families and novel domain architectures
    Sarah B. Reiff, Wallace F. Marshall · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
91. Discovery of novel harmine derivatives as potent, selective, and brain permeable GSK3β inhibitors with effective In vivo anti-AD activity
    Wenjie Liu, Limeng Wu, Xi Zeng, Huanhua Chen, Xinyue Ning, Xiaoyu Sun, Wen-Qiang Xuan, Ying Hao, Hongli Jia, Zhenshu Li et al. · 2025 · European Journal of Medicinal Chemistry
92. Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review
    Charlotte Jacob, Marleen Tollenaere, Hanane Kachar, Marie‐Claude Potier, Peter Paul De Deyn, Debby Van Dam · 2024 · Heliyon
93. Increases of SET level and translocation are correlated with tau hyperphosphorylation at ser202/thr205 in CA1 of Ts65Dn mice
    Emilie Dorard, Lucie Gorisse-Hussonnois, Chantal Guihenneuc‐Jouyaux, Christelle Albac, Marie‐Claude Potier, Bernadette Allinquant · 2016 · Neurobiology of Aging
94. Can Green Tea Polyphenols Improve Phenotypes Associated With Down Syndrome?
    Randall J. Roper, Charles R. Goodlett · 2018 · Elsevier eBooks
95. Molecular Pathways of Down Syndrome Critical Region Genes
    Ferdinando Di, Gaia Elena Berto · 2013 · InTech eBooks
96. An ELISA DYRK1A non-radioactive kinase assay suitable for the characterization of inhibitors
    Yong Liu, Tatyana Adayev, Yu‐Wen Hwang · 2017 · F1000Research
97. DnaK promotes autophosphorylation of DYRK1A and its family kinases in Escherichia coli-based cell-free protein expression
    Mizuki Aoyama, Ninako Kimura, Masato Yamakawa, Sora Suzuki, Koji Umezawa, Isao Kii · 2023 · Biochemical and Biophysical Research Communications
98. Human Cytomegalovirus Dysregulates Cellular Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases and Sonic Hedgehog Pathway Proteins in Neural Astrocyte and Placental Models
    Ece Egilmezer, Stuart T. Hamilton, Glen Lauw, Jasmine E. L. Follett, Eric Sonntag, Martin Schütz, Manfred Marschall, William D. Rawlinson · 2024 · Viruses
99. Challenges to congenital genetic disorders with “RNA-targeting” chemical compounds
    Yasushi Ogawa, Masatoshi Hagiwara · 2012 · Pharmacology & Therapeutics
100. Modeling Alzheimer’s disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior
     Cassia Overk, Emma Fiorini, Chiara Babolin, Marija Vukicevic, Catherine Morici, Rime Madani, Valérie Eligert, Marie H. Kosco‐Vilbois, Amanda J. Roberts, Ann Becker et al. · 2023 · Frontiers in Neuroscience